Hp-002
Preclinical
Hp-002 is one of 8 therapeutic programs targeting B-cell Non Hodgkin Lymphoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in B-Cell Non Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Tazverik
EEpizyme, Inc.
Phase 2
Surovatamig
AstraZenecaPhase 2
Rituxan
RochePhase 1
Yescarta
GileadPreclinical
Calquence
AstraZenecaPreclinical
AZD4512
AstraZenecaPreclinical
Hp-002
SShanghai Helioson Pharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Hp-002. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]